

-Image 1614

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))			Docket No. 114309-1004	
In Re Application Of: Gerald Horn				
Serial No. 09/705,526	Filing Date November 3, 2000	Examiner Z. Fay	Group Art Unit 1614	
Title: METHOD AND COMPOSITION WHICH REDUCES STIMULATION OF MUSCLES WHICH DILATE THE EYE				
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450				
37 CFR 1.97(b)				
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.				
37 CFR 1.97(c)				
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:				
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);				
OR				
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).				

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
114309-1004

In Re Application: Gerald Horn

NOV 03 2003

Serial No.
09/705,526

Filing Date
November 3, 2000

Examiner
Z. Fay

Group Art Unit
1614

**METHOD AND COMPOSITION WHICH REDUCES STIMULATION OF MUSCLES WHICH
THE EYE**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 10-30-2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Renee Street

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: October 30, 2003

Thomas C. Basso
Reg. No. 46,541
BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, IL 60690-1135
Phone: 312-807-4310

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gerald Horn
Appl. No.: 09/705,526
Conf. No.: 6897
Filed: November 3, 2000
Title: METHOD AND COMPOSITION WHICH REDUCES STIMULATION OF
MUSCLES WHICH DILATE THE EYE
Art Unit: 1614
Examiner: Z. Fay
Docket No.: 114309-1004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

OTHER DOCUMENTS

Nicola Iuglio, MD, *Ocular Effects of Topical Application of Dapiprazole in Man*, Glaucoma, 1984, Vol. 6, pp. 110-116.

Chou B., et al., *The Role of Pupil Size in Refractive Surgery*, February, 2001, www.refractivessource.com/doctors/clinical_pearls/role_pupil.htm.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,


BELL, BOYD & LLOYD LLC

BY 

Thomas C. Basso
Reg. No. 46,541
P.O. Box 1135
Chicago, Illinois 60690-1135
Phone: (312) 807-4310

Dated: October 30, 2003

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary) PTO Form 1449	Atty Docket No. 114309-1004	Application No. 09/705,526
	Applicant Gerald Horn	
	Filing Date Nov. 3, 2000	Group 1614



U.S. PATENT DOCUMENTS							
Examiner's Initials		Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS								
Examiner's Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

Examiner's Initials		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
		Nicola Iuglio, MD, <i>Ocular Effects of Topical Application of Dapiprazole in Man</i> , Glaucoma, 1984, Vol. 6, pp. 110-116.
		Chou B., et al., <i>The Role of Pupil Size in Refractive Surgery</i> , February, 2001, www.refractivessource.com/doctors/clinical_pearls/role_pupil.htm .

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	